

IHCP *banner page*

INDIANA HEALTH COVERAGE PROGRAMS BR201127 JULY 5, 2011



Billing guidelines for inpatient deliveries

Per *Chapter 8* of the *Indiana Health Coverage Programs (IHCP) Provider Manual*, the IHCP prohibits the use of V codes as a principal diagnosis code on a UB-04 claim form, except when using V codes as a principal diagnosis code for newborns, rehabilitation, or chemotherapy. On UB-04 claim forms filed for inpatient deliveries for the mother, V codes cannot be used as a primary diagnosis code. Claims that are incorrectly billed with a V code as the primary diagnosis for inpatient deliveries will be denied by HP and by the managed care entities.

Clarification of “brand medically necessary” policy for mental health drugs

The Office of Medicaid Policy and Planning (OMPP) has received anecdotal reports that suggest confusion regarding “brand medically necessary” prior authorization (PA) requirements, effective July 1, 2011, for mental health drugs. This topic was addressed in Indiana Health Coverage Programs (IHCP) bulletin [BT201111](#).

Since September 2001, Indiana Medicaid has had a policy of mandatory generic substitution when a generic equivalent is available. Exceptions to the policy have always required submission of a PA request from the provider. Previously, the mental health drug classes were exempt from this requirement. *Section 143* of *House Enrolled Act 1001* of the recently concluded 2010/2011 Indiana General Assembly removed this exemption. Effective July 1, 2011, mental health drug classes now require PA for drugs that are “brand medically necessary,” according to the same process as all other drug classes. This requirement has existed for other drug classes for some time. The change in the requirement brings mental health drug prescribing into alignment with the long-standing clinically and fiscally responsible policy.

Some reports received by the OMPP indicated that some providers mistakenly understood “therapeutic substitution” to be required. An example of therapeutic substitution is requiring the dispensing of the generically available atypical antipsy-

[Continue](#)

chotic risperidone for a different brand name atypical antipsychotic, such as Zyprexa or Abilify. Under Indiana law, therapeutic substitution is not permissible without prescriber approval. To clarify, the IHCP bulletin [BT201111](#) requires *prescribers to obtain PA when they indicate "brand medically necessary" for a mental health drug that has substitutable generic equivalents.*

QUESTIONS?

If you have questions about this publication, please contact Customer Assistance at (317) 655-3240 in the Indianapolis local area or toll-free at 1-800-577-1278.

COPIES OF THIS PUBLICATION

If you need additional copies of this publication, please [download them](#) from indianamedicaid.com. To receive e-mail notices of future IHCP publications, [subscribe](#) to IHCP E-mail Notifications.